EFFECTS OF INTRAVENOUS IRON SUPPLEMENTATION ON CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE AND IRON DEFICIENCY
Keywords:
сердечная недостаточность, дефицит железа, внутривенное железо, карбоксимальтозат железа, клинические исходы, функциональная способностьAbstract
To evaluate the impact of intravenous ferric carboxymaltose on secondary clinical outcomes in patients with chronic heart failure and iron deficiency in the randomized, double-blind, placebo-controlled trial of 135 patients with at least NYHA class II heart failure and 1 or more iron-deficiency criteria. Participants were randomized into the intervention (n = 68) and control groups (n = 67), with a 24-week follow-up. The composite endpoint was the change in the clinical status as measured by NYHA functional class, the Kansas City Cardiomyopathy Questionnaire (KCCQ), NT-proBNP, 6-minute walking distance (6MWD), and the number of heart failure hospitalizations. Major statistically significant benefits seen in the IV iron cohort compared with placebo were NYHA functional class improvement (≥1 class: 62% vs. 31%, p < 0.001), KCCQ scores (+18.6 vs. +6.2, p < 0.001), NT-proBNP levels (−420 vs. −110 pg/mL, p < 0.001), 6MWD (+64 vs. +24 meters, p < 0.001), and fewer hospitalizations (13.2% vs. 28.4%, p = 0.032). In our studied population, the administration of intravenous iron improves very significantly clinical condition, functional capacity and biological parameters, and also helps to reduce the number of hospitalizations in patients with chronic heart failure with reduced ejection fraction and deficiency of iron. The drug was well tolerated, with no meaningful differences in adverse events between the groups.
References
Jankowska, E.A. Iron deficiency: an ominous sign in patients with systolic chronic heart failure / E.A. Jankowska, P. Rozentryt, A. Witkowska [et al.] // European Heart Journal. – 2010. – Vol. 31, № 15. – P. 1872–1880. – DOI: 10.1093/eurheartj/ehq158.
Anand, I.S. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies / I.S. Anand, P. Gupta // Circulation. – 2018. – Vol. 138, № 1. – P. 80–98. – DOI: 10.1161/CIRCULATIONAHA.118.030099.
Von Haehling, S. Iron deficiency and cardiovascular disease / S. von Haehling, E.A. Jankowska, D.J. van Veldhuisen [et al.] // Nature Reviews Cardiology. – 2015. – Vol. 12, № 11. – P. 659–669. – DOI: 10.1038/nrcardio.2015.109.
Anker, S.D. Ferric carboxymaltose in patients with heart failure and iron deficiency / S.D. Anker, J. Comin Colet, G. Filippatos [et al.] // New England Journal of Medicine. – 2009. – Vol. 361, № 25. – P. 2436–2448. – DOI: 10.1056/NEJMoa0908355.
Ponikowski, P. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency / P. Ponikowski, D.J. van Veldhuisen, J. Comin-Colet [et al.] // European Heart Journal. – 2015. – Vol. 36, № 11. – P. 657–668. – DOI: 10.1093/eurheartj/ehu385.
Ponikowski, P. Ferric Carboxymaltose for Iron Deficiency at Discharge after Acute Heart Failure: A Multicentre, Double-Blind, Randomised, Controlled Trial / P. Ponikowski, B.A. Kirwan, S.D. Anker [et al.] // The Lancet. – 2020. – Vol. 396, № 10266. – P. 1895–1904. – DOI: 10.1016/S0140-6736(20)32339-4.
McDonagh, T.A. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure / T.A. McDonagh, M. Metra, M. Adamo [et al.] // European Heart Journal. – 2021. – Vol. 42, № 36. – P. 3599–3726. – DOI: 10.1093/eurheartj/ehab368.
